Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hyan Yee Kang has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action involves a distinct examiner and a distinct art unit. The current prosecution profile shows an active point of engagement with the patent office, suggesting a very specific technical focus. This action is the only active case for the applicant at this time. The focus on Biotechnology & Pharmaceuticals highlights the applicant's primary area of research and development in the life sciences.
Robert A Wax is the busiest examiner for the portfolio, managing 1 pending office action. This action accounts for the entirety of the pending workload, making the outcome of this specific review critical for the portfolio's progress. Practitioners should focus on the specific guidance provided by Robert A Wax, as he is the only examiner currently reviewing the applicant's applications. The resolution of this case will be the key driver of the portfolio's patent status in the near term.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WAX, ROBERT A | 1 | 25.7% | +3.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18756663 | BOWEL CLEANSING COMPOSITION WITH REDUCED DOSAGE ON THE DAY OF EXAMINATION | WAX, ROBERT A | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18756663 | BOWEL CLEANSING COMPOSITION WITH REDUCED DOSAGE ON THE DAY OF EXAMINATION | WAX, ROBERT A | 1615 | §102§103§112 | Non-Final OA | — | Pending | Jun 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHyan Yee Kang has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert A Wax has the most, with 1 of Hyan Yee Kang's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
